Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rite Aid Corporation Reports Fiscal 2023 First Quarter Results By: Rite Aid Corporation via Business Wire June 23, 2022 at 07:00 AM EDT Retail Comparable Store Prescriptions Increased 0.9 Percent – Comparable Store Non-COVID Acute Prescriptions Increased 11.9 Percent Revenues of $6.01 billion, Compared to Prior Year Revenues of $6.16 billion Net Loss per Share of $2.03, Compared to Prior Year Net Loss per Share of $0.24 Adjusted Net Loss per Share of $0.60, Compared to Prior Year Adjusted Net Income per Share of $0.38, Driven by Non-Cash Impairment Charges and Cycling Prior Year COVID Vaccination Benefit Adjusted EBITDA of $100.1 million, Compared to the Prior Year Adjusted EBITDA of $138.9 million Increases Fiscal 2023 Revenue and Maintains Fiscal 2023 Adjusted EBITDA Guidance Rite Aid Corporation (NYSE: RAD) today reported operating results for its first fiscal quarter ended May 28, 2022. “We continue to make strides on our journey to transform Rite Aid and define the modern pharmacy. In the first quarter we increased our non-COVID prescriptions, reduced SG&A, built momentum at Elixir and delivered solid results across the business. The entire Rite Aid team looks forward to advancing our pharmacists’ role in improving health outcomes,” said Heyward Donigan, president and CEO. Consolidated First Quarter Summary (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 6,014,583 $ 6,160,985 Net loss (110,191) (13,057) Adjusted EBITDA 100,130 138,877 For the first quarter the company reported a net loss of $110.2 million, or $2.03 loss per share, Adjusted Net Loss of $32.8 million, or $0.60 loss per share, and Adjusted EBITDA of $100.1 million, or 1.7 percent of revenues. Revenues for the quarter were $6.01 billion compared to revenues of $6.16 billion in the prior year’s quarter. First quarter net loss was $110.2 million, or $2.03 per share, compared to last year’s first quarter net loss of $13.1 million, or $0.24 per share. First quarter adjusted net loss was $32.8 million, or $0.60 per share, compared to last year’s first quarter adjusted net income of $20.9 million or $0.38 per share. The increase in adjusted net loss is due primarily to higher facility exit and impairment charges driven by the Company’s previously announced store closure decisions and a decrease in Adjusted EBITDA. These items were partially offset by an increase in gain on sale of assets resulting from script file sales of certain of the store closures. Retail Pharmacy Segment (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 4,345,356 $ 4,351,682 Adjusted EBITDA 73,682 94,914 Retail Pharmacy Segment revenues decreased 0.1 percent over the prior year quarter, driven by a reduction in COVID vaccine and testing revenue as well as store closures, offset by an increase in non-COVID prescriptions. Same store sales for the first quarter increased 4.6 percent over the prior year period, consisting of a 6.6 percent increase in pharmacy sales, partially offset by a 0.5 percent decrease in front-end sales. Front-end same store sales, excluding cigarettes and tobacco products, were flat. The number of prescriptions filled in same stores, adjusted to 30-day equivalents, increased 0.9 percent over the prior year period. Total non-COVID same store prescriptions increased 3.7 percent, with same store maintenance prescriptions increasing 1.4 percent and other same store acute prescriptions increasing 11.9 percent. Prescription sales accounted for 70.8 percent of total drugstore sales. Total store count at the end of the first quarter was 2,361. Retail Pharmacy Segment Adjusted EBITDA was $73.7 million, or 1.7 percent of revenues, for the first quarter compared to last year’s first quarter Adjusted EBITDA of $94.9 million, or 2.2 percent of revenues. The decline in Adjusted EBITDA was due to decreased gross profit, partially offset by a decrease in Adjusted EBITDA selling, general and administrative (SG&A) expenses of $40.5 million. Gross profit was negatively impacted by the decline in COVID-19 vaccinations and testing. The gross profit headwind from reduced COVID related services was partially offset by an increase in prescriptions filled and improved front end gross margin. SG&A expenses benefited from lower payroll, occupancy and other operating costs due to store closures and cost control initiatives. Pharmacy Services Segment (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 1,725,857 $ 1,872,282 Adjusted EBITDA 26,448 43,963 Pharmacy Services Segment revenues were $1.7 billion for the quarter, a decrease of 7.8 percent compared to the prior year quarter. The decrease in revenues was primarily the result of a planned decrease in Elixir Insurance membership and a previously announced client loss due to industry consolidation, offset by higher retained rebates from our new rebate aggregation arrangement and increased utilization of higher cost drugs. Pharmacy Services Segment Adjusted EBITDA was $26.4 million, or 1.5 percent of revenues, for the first quarter compared to last year’s first quarter Adjusted EBITDA of $44.0 million, or 2.4 percent of revenues. The reduction in Adjusted EBITDA resulted from the decline in revenues associated with lost clients, as discussed above, and an increase in the medical loss ratio at Elixir insurance, partially offset by higher retained rebates from our new rebate aggregation arrangement. Outlook for Fiscal 2023 The Company has increased its outlook for Fiscal 2023 revenues, due to increased utilization of higher cost drugs at Elixir and is maintaining its guidance for Adjusted EBITDA. Total revenues are expected to be between $23.6 billion and $24.0 billion in fiscal 2023. Retail Pharmacy Segment revenue is expected to be between $17.35 billion and $17.65 billion and Pharmacy Services Segment revenue is expected to be between $6.25 billion and $6.35 billion (net of any intercompany revenues to the Retail Pharmacy Segment). Net loss is expected to be between $246.3 million and $203.3 million. Our estimates for net loss have increased due to increased impairment charges for closed stores and an increase in interest expense due to recent and anticipated interest rate increases throughout the year. Adjusted EBITDA is expected to be between $460 million and $500 million. Retail Pharmacy Segment Adjusted EBITDA is expected to be between $320 million and $350 million and Pharmacy Services Segment Adjusted EBITDA is expected to be between $140 million and $150 million. Adjusted net loss per share is expected to be between $(1.19) and $(0.66). Capital expenditures are expected to be approximately $250 million, with a focus on investments in digital capabilities, technology, prescription file purchases, distribution center automation and store remodels. We expect to generate positive free cash flow in Fiscal 2023. Conference Call Broadcast Rite Aid will hold an analyst call at 8:30 a.m. Eastern Time today with remarks by Rite Aid's management team. The call will be broadcast via the Internet at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. Eastern Time on June 23, 2022 and ending at 11:59 p.m. Eastern Time on July 24, 2022. To access the replay of the call, telephone (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. Eastern Time today. The playback will be available until the company’s next conference call. About Rite Aid Corporation Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to Americans 365 days a year. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,300 retail pharmacy locations across 17 states. Through Elixir, we provide pharmacy benefits and services to millions of members nationwide. For more information, visit www.riteaid.com. Cautionary Statement Regarding Forward-Looking Statements Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Rite Aid's outlook and guidance for fiscal 2023; the continued impact of the global coronavirus (COVID-19) pandemic on Rite Aid’s business; Rite Aid’s store closure program; and any assumptions underlying any of the foregoing. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to: risks related to the prolonged impact of the COVID-19 global pandemic and the emerging new variants, including the government responses thereto; the impact of COVID-19 on our workforce, operations, stores, expenses, and supply chain, and the operations or behaviors of our customers, suppliers and business partners; our ability to successfully implement our store closure program and other strategies; the impact of our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms and our ability to satisfy our obligations and the other covenants contained in our debt agreements; outcome of pending or new litigation, including related to Opioids, “usual and customary” pricing or other matters; our ability to monetize the CMS receivable created in our Part D business; general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions (including changes to laws or regulations relating to labor or wages), as well as other factors that impact the markets in which we operate; the impact of private and public third-party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order; our ability to manage expenses and our investments in working capital; our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; our ability to achieve cost savings and other benefits of our restructuring efforts within our anticipated timeframe, if at all; the outcome of our continuing efforts to monitor and comply with applicable laws, regulations, policies and procedures; and our ability to partner and have relationships with health plans and health systems. These and other risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission (the “SEC”), which you are encouraged to read. To the extent that COVID-19 adversely affects our business and financial results, it may also have the effect of heightening many of such risk factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The degree to which COVID-19 may adversely affect Rite Aid’s results and operations, including its ability to achieve its outlook for fiscal 2023 guidance, will depend on numerous evolving factors and future developments, which are highly uncertain, including, but not limited to, federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 and emerging new variants and how quickly and to what extent normal economic and operating conditions can resume. As a result, the impact on Rite Aid’s financial and operating results cannot be reasonably estimated with specificity at this time, but the impact could be material. Rite Aid expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise. All references to “Company” and “Rite Aid” as used throughout this release refer to Rite Aid Corporation and its affiliates. Reconciliation of Non-GAAP Financial Measures Rite Aid separately reports financial results on the basis of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Adjusted EBITDA, Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A, which are non-GAAP financial measures. See the attached tables for a reconciliation of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Adjusted EBITDA to net income (loss), and net income (loss) per diluted share, which are the most directly comparable GAAP financial measures. Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share exclude amortization expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, gains or losses on debt modifications and retirements, LIFO adjustments, goodwill and intangible asset impairment charges, restructuring-related costs, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables. Rite Aid believes Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share serve as appropriate measures to be used in evaluating the performance of its business and help its investors better compare its operating performance over multiple periods. Adjusted EBITDA is defined as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility exit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, severance, restructuring-related costs, costs related to facility closures, gain or loss on sale of assets, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). The add back of LIFO (credit) charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share removes the entire impact of LIFO (credits) charges, and effectively reflects Rite Aid's results as if the company was on a FIFO inventory basis. Rite Aid believes Adjusted EBITDA serves as an appropriate measure in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors. Adjusted EBITDA Gross Profit includes LIFO adjustments, depreciation and amortization (COGS portion only) and other items. See the attached tables for a reconciliation of Adjusted EBITDA Gross Profit to Revenue, which is the most directly comparable GAAP financial measure. Adjusted EBITDA SG&A excludes depreciation and amortization (SG&A portion only), stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, and other items. See the attached tables for a reconciliation of Adjusted EBITDA SG&A to Revenue, which is the most directly comparable GAAP financial measure. The Company believes Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A serve as appropriate measures in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors. RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Dollars in thousands) (unaudited) May 28, 2022 February 26, 2022 ASSETS Current assets: Cash and cash equivalents $ 56,060 $ 39,721 Accounts receivable, net 1,449,745 1,343,496 Inventories, net of LIFO reserve of $487,173 and $487,173 1,974,759 1,959,389 Prepaid expenses and other current assets 88,860 106,749 Total current assets 3,569,424 3,449,355 Property, plant and equipment, net 985,121 989,167 Operating lease right-of-use assets 2,723,405 2,813,535 Goodwill 879,136 879,136 Other intangibles, net 282,950 291,196 Deferred tax assets 20,071 20,071 Other assets 89,666 86,543 Total assets $ 8,549,773 $ 8,529,003 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Current maturities of long-term debt and lease financing obligations $ 5,016 $ 5,544 Accounts payable 1,461,238 1,571,261 Accrued salaries, wages and other current liabilities 787,591 780,632 Current portion of operating lease liabilities 574,392 575,651 Total current liabilities 2,828,237 2,933,088 Long-term debt, less current maturities 3,026,456 2,732,986 Long-term operating lease liabilities 2,526,607 2,597,090 Lease financing obligations, less current maturities 14,392 14,830 Other noncurrent liabilities 162,457 151,976 Total liabilities 8,558,149 8,429,970 Commitments and contingencies - - Stockholders' equity: Common stock 55,623 55,752 Additional paid-in capital 5,913,210 5,910,299 Accumulated deficit (5,961,772 ) (5,851,581 ) Accumulated other comprehensive loss (15,437 ) (15,437 ) Total stockholders' equity (8,376 ) 99,033 Total liabilities and stockholders' equity $ 8,549,773 $ 8,529,003 RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in thousands, except per share amounts) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Revenues $ 6,014,583 $ 6,160,985 Costs and expenses: Cost of revenues 4,817,854 4,876,110 Selling, general and administrative expenses 1,217,929 1,245,362 Facility exit and impairment charges 66,571 8,831 Interest expense 48,119 49,121 Loss on debt retirements, net - 396 Gain on sale of assets, net (29,196 ) (6,558 ) 6,121,277 6,173,262 Loss before income taxes (106,694 ) (12,277 ) Income tax expense 3,497 780 Net loss $ (110,191 ) $ (13,057 ) Basic and diluted loss per share: Numerator for loss per share: Net loss attributable to common stockholders - basic and diluted $ (110,191 ) $ (13,057 ) Denominator: Basic and diluted weighted average shares 54,348 53,852 Basic and diluted loss per share $ (2.03 ) $ (0.24 ) RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 OPERATING ACTIVITIES: Net loss $ (110,191 ) $ (13,057 ) Adjustments to reconcile to net cash (used in) provided by operating activities: Depreciation and amortization 70,073 75,859 Facility exit and impairment charges 66,571 8,831 LIFO credit - (3,993 ) Change in allowances for uncollectible accounts receivable 3,763 - Gain on sale of assets, net (29,196 ) (6,558 ) Stock-based compensation expense 3,334 2,811 Loss on debt retirements, net - 396 Changes in operating assets and liabilities: Accounts receivable (104,458 ) (149,487 ) Inventories (15,827 ) 11,918 Accounts payable (137,572 ) 50,527 Operating lease right-of-use assets and operating lease liabilities (14,812 ) (5,909 ) Other assets 751 7,978 Other liabilities 15,327 34,559 Net cash (used in) provided by operating activities (252,237 ) 13,875 INVESTING ACTIVITIES: Payments for property, plant and equipment (73,176 ) (59,164 ) Intangible assets acquired (12,248 ) (5,436 ) Proceeds from dispositions of assets and investments 30,839 2,448 Proceeds from sale-leaseback transactions - 7,456 Net cash used in investing activities (54,585 ) (54,696 ) FINANCING ACTIVITIES: Net proceeds from revolver 291,000 39,000 Principal payments on long-term debt (977 ) (91,941 ) Change in zero balance cash accounts 33,691 51,957 Financing fees paid for early debt redemption - (2 ) Payments for taxes related to net share settlement of equity awards (553 ) (35 ) Deferred financing costs paid - (580 ) Net cash provided by (used in) financing activities 323,161 (1,601 ) Increase (decrease) in cash and cash equivalents 16,339 (42,422 ) Cash and cash equivalents, beginning of period 39,721 160,902 Cash and cash equivalents, end of period $ 56,060 $ 118,480 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL SEGMENT OPERATING INFORMATION (Dollars in thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Retail Pharmacy Segment Revenues (a) $ 4,345,356 $ 4,351,682 Cost of revenues (a) 3,247,999 3,181,748 Gross profit 1,097,357 1,169,934 LIFO credit - (3,993 ) FIFO gross profit 1,097,357 1,165,941 Adjusted EBITDA gross profit 1,106,652 1,168,338 Gross profit as a percentage of revenues 25.25 % 26.88 % LIFO credit as a percentage of revenues 0.00 % -0.09 % FIFO gross profit as a percentage of revenues 25.25 % 26.79 % Adjusted EBITDA gross profit as a percentage of revenues 25.47 % 26.85 % Selling, general and administrative expenses 1,117,214 1,156,039 Adjusted EBITDA selling, general and administrative expenses 1,032,970 1,073,424 Selling, general and administrative expenses as a percentage of revenues 25.71 % 26.57 % Adjusted EBITDA selling, general and administrative expenses as a percentage of revenues 23.77 % 24.67 % Cash interest expense 45,244 46,024 Non-cash interest expense 2,875 3,097 Total interest expense 48,119 49,121 Adjusted EBITDA 73,682 94,914 Adjusted EBITDA as a percentage of revenues 1.70 % 2.18 % Pharmacy Services Segment Revenues (a) $ 1,725,857 $ 1,872,282 Cost of revenues (a) 1,626,485 1,757,341 Gross profit 99,372 114,941 Gross profit as a percentage of revenues 5.76 % 6.14 % Adjusted EBITDA 26,448 43,963 Adjusted EBITDA as a percentage of revenues 1.53 % 2.35 % (a) - Revenues and cost of revenues include $56,630 and $62,979 of inter-segment activity for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively, that is eliminated in consolidation. RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (In thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Reconciliation of net loss to adjusted EBITDA: Net loss $ (110,191 ) $ (13,057 ) Adjustments: Interest expense 48,119 49,121 Income tax expense 3,497 780 Depreciation and amortization 70,073 75,859 LIFO credit - (3,993 ) Facility exit and impairment charges 66,571 8,831 Loss on debt retirements, net - 396 Merger and Acquisition-related costs - 3,886 Stock-based compensation expense 3,334 2,811 Restructuring-related costs 22,646 5,932 Inventory write-downs related to store closings 7,955 472 Litigation and other contractual settlements 18,271 14,000 Gain on sale of assets, net (29,196 ) (6,558 ) Other (949 ) 397 Adjusted EBITDA $ 100,130 $ 138,877 Percent of revenues 1.66 % 2.25 % RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION ADJUSTED NET (LOSS) INCOME (Dollars in thousands, except per share amounts) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Net loss $ (110,191 ) $ (13,057 ) Add back - Income tax expense 3,497 780 Loss before income taxes (106,694 ) (12,277 ) Adjustments: Amortization expense 20,626 20,460 LIFO credit - (3,993 ) Loss on debt retirements, net - 396 Merger and Acquisition-related costs - 3,886 Restructuring-related costs 22,646 5,932 Litigation and other contractual settlements 18,271 14,000 Adjusted (loss) income before income taxes (45,151 ) 28,404 Adjusted income tax (benefit) expense (a) (12,322 ) 7,470 Adjusted net (loss) income $ (32,829 ) $ 20,934 Adjusted net (loss) income per diluted share: Numerator for adjusted net (loss) income per diluted share: Adjusted net (loss) income $ (32,829 ) $ 20,934 Denominator: Basic weighted average shares 54,348 53,852 Outstanding options and restricted shares, net - 971 Diluted weighted average shares 54,348 54,823 Net loss per diluted share $ (2.03 ) $ (0.24 ) Adjusted net (loss) income per diluted share $ (0.60 ) $ 0.38 (a) The fiscal year 2023 and 2022 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL's, state credits and valuation allowance, was used for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively. RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT AND RECONCILIATION OF ADJUSTED EBITDA SELLING, GENERAL AND ADMINISTRATIVE EXPENSES- RETAIL PHARMACY SEGMENT (In thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Reconciliation of adjusted EBITDA gross profit: Revenues $ 4,345,356 $ 4,351,682 Gross Profit 1,097,357 1,169,934 Addback: LIFO credit - (3,993 ) Depreciation and amortization (cost of goods sold portion only) 2,893 2,097 Other 6,402 300 Adjusted EBITDA gross profit $ 1,106,652 $ 1,168,338 Percent of revenues 25.47 % 26.85 % Reconciliation of adjusted EBITDA selling, general and administrative expenses: Revenues $ 4,345,356 $ 4,351,682 Selling, general and administrative expenses 1,117,214 1,156,039 Less: Depreciation and amortization (SG&A portion only) 53,215 59,768 Stock-based compensation expense 3,102 2,771 Merger and Acquisition-related costs - 3,886 Restructuring-related costs 17,371 1,621 Litigation and other contractual settlements 9,952 14,000 Other 604 569 Adjusted EBITDA selling, general and administrative expenses $ 1,032,970 $ 1,073,424 Percent of revenues 23.77 % 24.67 % Adjusted EBITDA $ 73,682 $ 94,914 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited) Guidance Range Low High Total Revenues $ 23,600,000 $ 24,000,000 Pharmacy Services Segment Revenues $ 6,250,000 $ 6,350,000 Gross Capital Expenditures $ 250,000 $ 250,000 Reconciliation of net loss to adjusted EBITDA: Net loss $ (246,300 ) $ (203,300 ) Adjustments: Interest expense 210,000 210,000 Income tax benefit (15,000 ) (18,000 ) Depreciation and amortization 290,000 290,000 LIFO charge 15,000 15,000 Facility exit and impairment charges 130,000 130,000 Restructuring-related costs 60,000 60,000 Litigation and other contractual settlements 18,300 18,300 Gain on sale of assets, net (35,000 ) (35,000 ) Other 33,000 33,000 Adjusted EBITDA $ 460,000 $ 500,000 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET LOSS GUIDANCE YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited) Guidance Range Low High Net loss $ (246,300 ) $ (203,300 ) Add back - income tax benefit (15,000 ) (18,000 ) Loss before income taxes (261,300 ) (221,300 ) Adjustments: Amortization expense 79,000 79,000 LIFO charge 15,000 15,000 Restructuring-related costs 60,000 60,000 Litigation and other contractual settlements 18,300 18,300 Adjusted loss before adjusted income taxes (89,000 ) (49,000 ) Adjusted income tax benefit (24,000 ) (13,000 ) Adjusted net loss $ (65,000 ) $ (36,000 ) Diluted adjusted net loss per share $ (1.19 ) $ (0.66 ) View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005204/en/Contacts INVESTORS: Byron Purcell (717) 975-3710 investor@riteaid.com MEDIA: Joy Errico Seusing (203) 970-5559 press@riteaid.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Rite Aid Corporation Reports Fiscal 2023 First Quarter Results By: Rite Aid Corporation via Business Wire June 23, 2022 at 07:00 AM EDT Retail Comparable Store Prescriptions Increased 0.9 Percent – Comparable Store Non-COVID Acute Prescriptions Increased 11.9 Percent Revenues of $6.01 billion, Compared to Prior Year Revenues of $6.16 billion Net Loss per Share of $2.03, Compared to Prior Year Net Loss per Share of $0.24 Adjusted Net Loss per Share of $0.60, Compared to Prior Year Adjusted Net Income per Share of $0.38, Driven by Non-Cash Impairment Charges and Cycling Prior Year COVID Vaccination Benefit Adjusted EBITDA of $100.1 million, Compared to the Prior Year Adjusted EBITDA of $138.9 million Increases Fiscal 2023 Revenue and Maintains Fiscal 2023 Adjusted EBITDA Guidance Rite Aid Corporation (NYSE: RAD) today reported operating results for its first fiscal quarter ended May 28, 2022. “We continue to make strides on our journey to transform Rite Aid and define the modern pharmacy. In the first quarter we increased our non-COVID prescriptions, reduced SG&A, built momentum at Elixir and delivered solid results across the business. The entire Rite Aid team looks forward to advancing our pharmacists’ role in improving health outcomes,” said Heyward Donigan, president and CEO. Consolidated First Quarter Summary (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 6,014,583 $ 6,160,985 Net loss (110,191) (13,057) Adjusted EBITDA 100,130 138,877 For the first quarter the company reported a net loss of $110.2 million, or $2.03 loss per share, Adjusted Net Loss of $32.8 million, or $0.60 loss per share, and Adjusted EBITDA of $100.1 million, or 1.7 percent of revenues. Revenues for the quarter were $6.01 billion compared to revenues of $6.16 billion in the prior year’s quarter. First quarter net loss was $110.2 million, or $2.03 per share, compared to last year’s first quarter net loss of $13.1 million, or $0.24 per share. First quarter adjusted net loss was $32.8 million, or $0.60 per share, compared to last year’s first quarter adjusted net income of $20.9 million or $0.38 per share. The increase in adjusted net loss is due primarily to higher facility exit and impairment charges driven by the Company’s previously announced store closure decisions and a decrease in Adjusted EBITDA. These items were partially offset by an increase in gain on sale of assets resulting from script file sales of certain of the store closures. Retail Pharmacy Segment (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 4,345,356 $ 4,351,682 Adjusted EBITDA 73,682 94,914 Retail Pharmacy Segment revenues decreased 0.1 percent over the prior year quarter, driven by a reduction in COVID vaccine and testing revenue as well as store closures, offset by an increase in non-COVID prescriptions. Same store sales for the first quarter increased 4.6 percent over the prior year period, consisting of a 6.6 percent increase in pharmacy sales, partially offset by a 0.5 percent decrease in front-end sales. Front-end same store sales, excluding cigarettes and tobacco products, were flat. The number of prescriptions filled in same stores, adjusted to 30-day equivalents, increased 0.9 percent over the prior year period. Total non-COVID same store prescriptions increased 3.7 percent, with same store maintenance prescriptions increasing 1.4 percent and other same store acute prescriptions increasing 11.9 percent. Prescription sales accounted for 70.8 percent of total drugstore sales. Total store count at the end of the first quarter was 2,361. Retail Pharmacy Segment Adjusted EBITDA was $73.7 million, or 1.7 percent of revenues, for the first quarter compared to last year’s first quarter Adjusted EBITDA of $94.9 million, or 2.2 percent of revenues. The decline in Adjusted EBITDA was due to decreased gross profit, partially offset by a decrease in Adjusted EBITDA selling, general and administrative (SG&A) expenses of $40.5 million. Gross profit was negatively impacted by the decline in COVID-19 vaccinations and testing. The gross profit headwind from reduced COVID related services was partially offset by an increase in prescriptions filled and improved front end gross margin. SG&A expenses benefited from lower payroll, occupancy and other operating costs due to store closures and cost control initiatives. Pharmacy Services Segment (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 1,725,857 $ 1,872,282 Adjusted EBITDA 26,448 43,963 Pharmacy Services Segment revenues were $1.7 billion for the quarter, a decrease of 7.8 percent compared to the prior year quarter. The decrease in revenues was primarily the result of a planned decrease in Elixir Insurance membership and a previously announced client loss due to industry consolidation, offset by higher retained rebates from our new rebate aggregation arrangement and increased utilization of higher cost drugs. Pharmacy Services Segment Adjusted EBITDA was $26.4 million, or 1.5 percent of revenues, for the first quarter compared to last year’s first quarter Adjusted EBITDA of $44.0 million, or 2.4 percent of revenues. The reduction in Adjusted EBITDA resulted from the decline in revenues associated with lost clients, as discussed above, and an increase in the medical loss ratio at Elixir insurance, partially offset by higher retained rebates from our new rebate aggregation arrangement. Outlook for Fiscal 2023 The Company has increased its outlook for Fiscal 2023 revenues, due to increased utilization of higher cost drugs at Elixir and is maintaining its guidance for Adjusted EBITDA. Total revenues are expected to be between $23.6 billion and $24.0 billion in fiscal 2023. Retail Pharmacy Segment revenue is expected to be between $17.35 billion and $17.65 billion and Pharmacy Services Segment revenue is expected to be between $6.25 billion and $6.35 billion (net of any intercompany revenues to the Retail Pharmacy Segment). Net loss is expected to be between $246.3 million and $203.3 million. Our estimates for net loss have increased due to increased impairment charges for closed stores and an increase in interest expense due to recent and anticipated interest rate increases throughout the year. Adjusted EBITDA is expected to be between $460 million and $500 million. Retail Pharmacy Segment Adjusted EBITDA is expected to be between $320 million and $350 million and Pharmacy Services Segment Adjusted EBITDA is expected to be between $140 million and $150 million. Adjusted net loss per share is expected to be between $(1.19) and $(0.66). Capital expenditures are expected to be approximately $250 million, with a focus on investments in digital capabilities, technology, prescription file purchases, distribution center automation and store remodels. We expect to generate positive free cash flow in Fiscal 2023. Conference Call Broadcast Rite Aid will hold an analyst call at 8:30 a.m. Eastern Time today with remarks by Rite Aid's management team. The call will be broadcast via the Internet at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. Eastern Time on June 23, 2022 and ending at 11:59 p.m. Eastern Time on July 24, 2022. To access the replay of the call, telephone (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. Eastern Time today. The playback will be available until the company’s next conference call. About Rite Aid Corporation Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to Americans 365 days a year. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,300 retail pharmacy locations across 17 states. Through Elixir, we provide pharmacy benefits and services to millions of members nationwide. For more information, visit www.riteaid.com. Cautionary Statement Regarding Forward-Looking Statements Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Rite Aid's outlook and guidance for fiscal 2023; the continued impact of the global coronavirus (COVID-19) pandemic on Rite Aid’s business; Rite Aid’s store closure program; and any assumptions underlying any of the foregoing. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to: risks related to the prolonged impact of the COVID-19 global pandemic and the emerging new variants, including the government responses thereto; the impact of COVID-19 on our workforce, operations, stores, expenses, and supply chain, and the operations or behaviors of our customers, suppliers and business partners; our ability to successfully implement our store closure program and other strategies; the impact of our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms and our ability to satisfy our obligations and the other covenants contained in our debt agreements; outcome of pending or new litigation, including related to Opioids, “usual and customary” pricing or other matters; our ability to monetize the CMS receivable created in our Part D business; general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions (including changes to laws or regulations relating to labor or wages), as well as other factors that impact the markets in which we operate; the impact of private and public third-party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order; our ability to manage expenses and our investments in working capital; our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; our ability to achieve cost savings and other benefits of our restructuring efforts within our anticipated timeframe, if at all; the outcome of our continuing efforts to monitor and comply with applicable laws, regulations, policies and procedures; and our ability to partner and have relationships with health plans and health systems. These and other risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission (the “SEC”), which you are encouraged to read. To the extent that COVID-19 adversely affects our business and financial results, it may also have the effect of heightening many of such risk factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The degree to which COVID-19 may adversely affect Rite Aid’s results and operations, including its ability to achieve its outlook for fiscal 2023 guidance, will depend on numerous evolving factors and future developments, which are highly uncertain, including, but not limited to, federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 and emerging new variants and how quickly and to what extent normal economic and operating conditions can resume. As a result, the impact on Rite Aid’s financial and operating results cannot be reasonably estimated with specificity at this time, but the impact could be material. Rite Aid expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise. All references to “Company” and “Rite Aid” as used throughout this release refer to Rite Aid Corporation and its affiliates. Reconciliation of Non-GAAP Financial Measures Rite Aid separately reports financial results on the basis of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Adjusted EBITDA, Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A, which are non-GAAP financial measures. See the attached tables for a reconciliation of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Adjusted EBITDA to net income (loss), and net income (loss) per diluted share, which are the most directly comparable GAAP financial measures. Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share exclude amortization expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, gains or losses on debt modifications and retirements, LIFO adjustments, goodwill and intangible asset impairment charges, restructuring-related costs, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables. Rite Aid believes Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share serve as appropriate measures to be used in evaluating the performance of its business and help its investors better compare its operating performance over multiple periods. Adjusted EBITDA is defined as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility exit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, severance, restructuring-related costs, costs related to facility closures, gain or loss on sale of assets, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). The add back of LIFO (credit) charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share removes the entire impact of LIFO (credits) charges, and effectively reflects Rite Aid's results as if the company was on a FIFO inventory basis. Rite Aid believes Adjusted EBITDA serves as an appropriate measure in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors. Adjusted EBITDA Gross Profit includes LIFO adjustments, depreciation and amortization (COGS portion only) and other items. See the attached tables for a reconciliation of Adjusted EBITDA Gross Profit to Revenue, which is the most directly comparable GAAP financial measure. Adjusted EBITDA SG&A excludes depreciation and amortization (SG&A portion only), stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, and other items. See the attached tables for a reconciliation of Adjusted EBITDA SG&A to Revenue, which is the most directly comparable GAAP financial measure. The Company believes Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A serve as appropriate measures in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors. RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Dollars in thousands) (unaudited) May 28, 2022 February 26, 2022 ASSETS Current assets: Cash and cash equivalents $ 56,060 $ 39,721 Accounts receivable, net 1,449,745 1,343,496 Inventories, net of LIFO reserve of $487,173 and $487,173 1,974,759 1,959,389 Prepaid expenses and other current assets 88,860 106,749 Total current assets 3,569,424 3,449,355 Property, plant and equipment, net 985,121 989,167 Operating lease right-of-use assets 2,723,405 2,813,535 Goodwill 879,136 879,136 Other intangibles, net 282,950 291,196 Deferred tax assets 20,071 20,071 Other assets 89,666 86,543 Total assets $ 8,549,773 $ 8,529,003 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Current maturities of long-term debt and lease financing obligations $ 5,016 $ 5,544 Accounts payable 1,461,238 1,571,261 Accrued salaries, wages and other current liabilities 787,591 780,632 Current portion of operating lease liabilities 574,392 575,651 Total current liabilities 2,828,237 2,933,088 Long-term debt, less current maturities 3,026,456 2,732,986 Long-term operating lease liabilities 2,526,607 2,597,090 Lease financing obligations, less current maturities 14,392 14,830 Other noncurrent liabilities 162,457 151,976 Total liabilities 8,558,149 8,429,970 Commitments and contingencies - - Stockholders' equity: Common stock 55,623 55,752 Additional paid-in capital 5,913,210 5,910,299 Accumulated deficit (5,961,772 ) (5,851,581 ) Accumulated other comprehensive loss (15,437 ) (15,437 ) Total stockholders' equity (8,376 ) 99,033 Total liabilities and stockholders' equity $ 8,549,773 $ 8,529,003 RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in thousands, except per share amounts) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Revenues $ 6,014,583 $ 6,160,985 Costs and expenses: Cost of revenues 4,817,854 4,876,110 Selling, general and administrative expenses 1,217,929 1,245,362 Facility exit and impairment charges 66,571 8,831 Interest expense 48,119 49,121 Loss on debt retirements, net - 396 Gain on sale of assets, net (29,196 ) (6,558 ) 6,121,277 6,173,262 Loss before income taxes (106,694 ) (12,277 ) Income tax expense 3,497 780 Net loss $ (110,191 ) $ (13,057 ) Basic and diluted loss per share: Numerator for loss per share: Net loss attributable to common stockholders - basic and diluted $ (110,191 ) $ (13,057 ) Denominator: Basic and diluted weighted average shares 54,348 53,852 Basic and diluted loss per share $ (2.03 ) $ (0.24 ) RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 OPERATING ACTIVITIES: Net loss $ (110,191 ) $ (13,057 ) Adjustments to reconcile to net cash (used in) provided by operating activities: Depreciation and amortization 70,073 75,859 Facility exit and impairment charges 66,571 8,831 LIFO credit - (3,993 ) Change in allowances for uncollectible accounts receivable 3,763 - Gain on sale of assets, net (29,196 ) (6,558 ) Stock-based compensation expense 3,334 2,811 Loss on debt retirements, net - 396 Changes in operating assets and liabilities: Accounts receivable (104,458 ) (149,487 ) Inventories (15,827 ) 11,918 Accounts payable (137,572 ) 50,527 Operating lease right-of-use assets and operating lease liabilities (14,812 ) (5,909 ) Other assets 751 7,978 Other liabilities 15,327 34,559 Net cash (used in) provided by operating activities (252,237 ) 13,875 INVESTING ACTIVITIES: Payments for property, plant and equipment (73,176 ) (59,164 ) Intangible assets acquired (12,248 ) (5,436 ) Proceeds from dispositions of assets and investments 30,839 2,448 Proceeds from sale-leaseback transactions - 7,456 Net cash used in investing activities (54,585 ) (54,696 ) FINANCING ACTIVITIES: Net proceeds from revolver 291,000 39,000 Principal payments on long-term debt (977 ) (91,941 ) Change in zero balance cash accounts 33,691 51,957 Financing fees paid for early debt redemption - (2 ) Payments for taxes related to net share settlement of equity awards (553 ) (35 ) Deferred financing costs paid - (580 ) Net cash provided by (used in) financing activities 323,161 (1,601 ) Increase (decrease) in cash and cash equivalents 16,339 (42,422 ) Cash and cash equivalents, beginning of period 39,721 160,902 Cash and cash equivalents, end of period $ 56,060 $ 118,480 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL SEGMENT OPERATING INFORMATION (Dollars in thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Retail Pharmacy Segment Revenues (a) $ 4,345,356 $ 4,351,682 Cost of revenues (a) 3,247,999 3,181,748 Gross profit 1,097,357 1,169,934 LIFO credit - (3,993 ) FIFO gross profit 1,097,357 1,165,941 Adjusted EBITDA gross profit 1,106,652 1,168,338 Gross profit as a percentage of revenues 25.25 % 26.88 % LIFO credit as a percentage of revenues 0.00 % -0.09 % FIFO gross profit as a percentage of revenues 25.25 % 26.79 % Adjusted EBITDA gross profit as a percentage of revenues 25.47 % 26.85 % Selling, general and administrative expenses 1,117,214 1,156,039 Adjusted EBITDA selling, general and administrative expenses 1,032,970 1,073,424 Selling, general and administrative expenses as a percentage of revenues 25.71 % 26.57 % Adjusted EBITDA selling, general and administrative expenses as a percentage of revenues 23.77 % 24.67 % Cash interest expense 45,244 46,024 Non-cash interest expense 2,875 3,097 Total interest expense 48,119 49,121 Adjusted EBITDA 73,682 94,914 Adjusted EBITDA as a percentage of revenues 1.70 % 2.18 % Pharmacy Services Segment Revenues (a) $ 1,725,857 $ 1,872,282 Cost of revenues (a) 1,626,485 1,757,341 Gross profit 99,372 114,941 Gross profit as a percentage of revenues 5.76 % 6.14 % Adjusted EBITDA 26,448 43,963 Adjusted EBITDA as a percentage of revenues 1.53 % 2.35 % (a) - Revenues and cost of revenues include $56,630 and $62,979 of inter-segment activity for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively, that is eliminated in consolidation. RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (In thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Reconciliation of net loss to adjusted EBITDA: Net loss $ (110,191 ) $ (13,057 ) Adjustments: Interest expense 48,119 49,121 Income tax expense 3,497 780 Depreciation and amortization 70,073 75,859 LIFO credit - (3,993 ) Facility exit and impairment charges 66,571 8,831 Loss on debt retirements, net - 396 Merger and Acquisition-related costs - 3,886 Stock-based compensation expense 3,334 2,811 Restructuring-related costs 22,646 5,932 Inventory write-downs related to store closings 7,955 472 Litigation and other contractual settlements 18,271 14,000 Gain on sale of assets, net (29,196 ) (6,558 ) Other (949 ) 397 Adjusted EBITDA $ 100,130 $ 138,877 Percent of revenues 1.66 % 2.25 % RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION ADJUSTED NET (LOSS) INCOME (Dollars in thousands, except per share amounts) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Net loss $ (110,191 ) $ (13,057 ) Add back - Income tax expense 3,497 780 Loss before income taxes (106,694 ) (12,277 ) Adjustments: Amortization expense 20,626 20,460 LIFO credit - (3,993 ) Loss on debt retirements, net - 396 Merger and Acquisition-related costs - 3,886 Restructuring-related costs 22,646 5,932 Litigation and other contractual settlements 18,271 14,000 Adjusted (loss) income before income taxes (45,151 ) 28,404 Adjusted income tax (benefit) expense (a) (12,322 ) 7,470 Adjusted net (loss) income $ (32,829 ) $ 20,934 Adjusted net (loss) income per diluted share: Numerator for adjusted net (loss) income per diluted share: Adjusted net (loss) income $ (32,829 ) $ 20,934 Denominator: Basic weighted average shares 54,348 53,852 Outstanding options and restricted shares, net - 971 Diluted weighted average shares 54,348 54,823 Net loss per diluted share $ (2.03 ) $ (0.24 ) Adjusted net (loss) income per diluted share $ (0.60 ) $ 0.38 (a) The fiscal year 2023 and 2022 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL's, state credits and valuation allowance, was used for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively. RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT AND RECONCILIATION OF ADJUSTED EBITDA SELLING, GENERAL AND ADMINISTRATIVE EXPENSES- RETAIL PHARMACY SEGMENT (In thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Reconciliation of adjusted EBITDA gross profit: Revenues $ 4,345,356 $ 4,351,682 Gross Profit 1,097,357 1,169,934 Addback: LIFO credit - (3,993 ) Depreciation and amortization (cost of goods sold portion only) 2,893 2,097 Other 6,402 300 Adjusted EBITDA gross profit $ 1,106,652 $ 1,168,338 Percent of revenues 25.47 % 26.85 % Reconciliation of adjusted EBITDA selling, general and administrative expenses: Revenues $ 4,345,356 $ 4,351,682 Selling, general and administrative expenses 1,117,214 1,156,039 Less: Depreciation and amortization (SG&A portion only) 53,215 59,768 Stock-based compensation expense 3,102 2,771 Merger and Acquisition-related costs - 3,886 Restructuring-related costs 17,371 1,621 Litigation and other contractual settlements 9,952 14,000 Other 604 569 Adjusted EBITDA selling, general and administrative expenses $ 1,032,970 $ 1,073,424 Percent of revenues 23.77 % 24.67 % Adjusted EBITDA $ 73,682 $ 94,914 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited) Guidance Range Low High Total Revenues $ 23,600,000 $ 24,000,000 Pharmacy Services Segment Revenues $ 6,250,000 $ 6,350,000 Gross Capital Expenditures $ 250,000 $ 250,000 Reconciliation of net loss to adjusted EBITDA: Net loss $ (246,300 ) $ (203,300 ) Adjustments: Interest expense 210,000 210,000 Income tax benefit (15,000 ) (18,000 ) Depreciation and amortization 290,000 290,000 LIFO charge 15,000 15,000 Facility exit and impairment charges 130,000 130,000 Restructuring-related costs 60,000 60,000 Litigation and other contractual settlements 18,300 18,300 Gain on sale of assets, net (35,000 ) (35,000 ) Other 33,000 33,000 Adjusted EBITDA $ 460,000 $ 500,000 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET LOSS GUIDANCE YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited) Guidance Range Low High Net loss $ (246,300 ) $ (203,300 ) Add back - income tax benefit (15,000 ) (18,000 ) Loss before income taxes (261,300 ) (221,300 ) Adjustments: Amortization expense 79,000 79,000 LIFO charge 15,000 15,000 Restructuring-related costs 60,000 60,000 Litigation and other contractual settlements 18,300 18,300 Adjusted loss before adjusted income taxes (89,000 ) (49,000 ) Adjusted income tax benefit (24,000 ) (13,000 ) Adjusted net loss $ (65,000 ) $ (36,000 ) Diluted adjusted net loss per share $ (1.19 ) $ (0.66 ) View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005204/en/Contacts INVESTORS: Byron Purcell (717) 975-3710 investor@riteaid.com MEDIA: Joy Errico Seusing (203) 970-5559 press@riteaid.com
Retail Comparable Store Prescriptions Increased 0.9 Percent – Comparable Store Non-COVID Acute Prescriptions Increased 11.9 Percent Revenues of $6.01 billion, Compared to Prior Year Revenues of $6.16 billion Net Loss per Share of $2.03, Compared to Prior Year Net Loss per Share of $0.24 Adjusted Net Loss per Share of $0.60, Compared to Prior Year Adjusted Net Income per Share of $0.38, Driven by Non-Cash Impairment Charges and Cycling Prior Year COVID Vaccination Benefit Adjusted EBITDA of $100.1 million, Compared to the Prior Year Adjusted EBITDA of $138.9 million Increases Fiscal 2023 Revenue and Maintains Fiscal 2023 Adjusted EBITDA Guidance
Rite Aid Corporation (NYSE: RAD) today reported operating results for its first fiscal quarter ended May 28, 2022. “We continue to make strides on our journey to transform Rite Aid and define the modern pharmacy. In the first quarter we increased our non-COVID prescriptions, reduced SG&A, built momentum at Elixir and delivered solid results across the business. The entire Rite Aid team looks forward to advancing our pharmacists’ role in improving health outcomes,” said Heyward Donigan, president and CEO. Consolidated First Quarter Summary (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 6,014,583 $ 6,160,985 Net loss (110,191) (13,057) Adjusted EBITDA 100,130 138,877 For the first quarter the company reported a net loss of $110.2 million, or $2.03 loss per share, Adjusted Net Loss of $32.8 million, or $0.60 loss per share, and Adjusted EBITDA of $100.1 million, or 1.7 percent of revenues. Revenues for the quarter were $6.01 billion compared to revenues of $6.16 billion in the prior year’s quarter. First quarter net loss was $110.2 million, or $2.03 per share, compared to last year’s first quarter net loss of $13.1 million, or $0.24 per share. First quarter adjusted net loss was $32.8 million, or $0.60 per share, compared to last year’s first quarter adjusted net income of $20.9 million or $0.38 per share. The increase in adjusted net loss is due primarily to higher facility exit and impairment charges driven by the Company’s previously announced store closure decisions and a decrease in Adjusted EBITDA. These items were partially offset by an increase in gain on sale of assets resulting from script file sales of certain of the store closures. Retail Pharmacy Segment (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 4,345,356 $ 4,351,682 Adjusted EBITDA 73,682 94,914 Retail Pharmacy Segment revenues decreased 0.1 percent over the prior year quarter, driven by a reduction in COVID vaccine and testing revenue as well as store closures, offset by an increase in non-COVID prescriptions. Same store sales for the first quarter increased 4.6 percent over the prior year period, consisting of a 6.6 percent increase in pharmacy sales, partially offset by a 0.5 percent decrease in front-end sales. Front-end same store sales, excluding cigarettes and tobacco products, were flat. The number of prescriptions filled in same stores, adjusted to 30-day equivalents, increased 0.9 percent over the prior year period. Total non-COVID same store prescriptions increased 3.7 percent, with same store maintenance prescriptions increasing 1.4 percent and other same store acute prescriptions increasing 11.9 percent. Prescription sales accounted for 70.8 percent of total drugstore sales. Total store count at the end of the first quarter was 2,361. Retail Pharmacy Segment Adjusted EBITDA was $73.7 million, or 1.7 percent of revenues, for the first quarter compared to last year’s first quarter Adjusted EBITDA of $94.9 million, or 2.2 percent of revenues. The decline in Adjusted EBITDA was due to decreased gross profit, partially offset by a decrease in Adjusted EBITDA selling, general and administrative (SG&A) expenses of $40.5 million. Gross profit was negatively impacted by the decline in COVID-19 vaccinations and testing. The gross profit headwind from reduced COVID related services was partially offset by an increase in prescriptions filled and improved front end gross margin. SG&A expenses benefited from lower payroll, occupancy and other operating costs due to store closures and cost control initiatives. Pharmacy Services Segment (dollars in thousands) Thirteen Week Period Ended May 28, 2022 May 29, 2021 Revenues $ 1,725,857 $ 1,872,282 Adjusted EBITDA 26,448 43,963 Pharmacy Services Segment revenues were $1.7 billion for the quarter, a decrease of 7.8 percent compared to the prior year quarter. The decrease in revenues was primarily the result of a planned decrease in Elixir Insurance membership and a previously announced client loss due to industry consolidation, offset by higher retained rebates from our new rebate aggregation arrangement and increased utilization of higher cost drugs. Pharmacy Services Segment Adjusted EBITDA was $26.4 million, or 1.5 percent of revenues, for the first quarter compared to last year’s first quarter Adjusted EBITDA of $44.0 million, or 2.4 percent of revenues. The reduction in Adjusted EBITDA resulted from the decline in revenues associated with lost clients, as discussed above, and an increase in the medical loss ratio at Elixir insurance, partially offset by higher retained rebates from our new rebate aggregation arrangement. Outlook for Fiscal 2023 The Company has increased its outlook for Fiscal 2023 revenues, due to increased utilization of higher cost drugs at Elixir and is maintaining its guidance for Adjusted EBITDA. Total revenues are expected to be between $23.6 billion and $24.0 billion in fiscal 2023. Retail Pharmacy Segment revenue is expected to be between $17.35 billion and $17.65 billion and Pharmacy Services Segment revenue is expected to be between $6.25 billion and $6.35 billion (net of any intercompany revenues to the Retail Pharmacy Segment). Net loss is expected to be between $246.3 million and $203.3 million. Our estimates for net loss have increased due to increased impairment charges for closed stores and an increase in interest expense due to recent and anticipated interest rate increases throughout the year. Adjusted EBITDA is expected to be between $460 million and $500 million. Retail Pharmacy Segment Adjusted EBITDA is expected to be between $320 million and $350 million and Pharmacy Services Segment Adjusted EBITDA is expected to be between $140 million and $150 million. Adjusted net loss per share is expected to be between $(1.19) and $(0.66). Capital expenditures are expected to be approximately $250 million, with a focus on investments in digital capabilities, technology, prescription file purchases, distribution center automation and store remodels. We expect to generate positive free cash flow in Fiscal 2023. Conference Call Broadcast Rite Aid will hold an analyst call at 8:30 a.m. Eastern Time today with remarks by Rite Aid's management team. The call will be broadcast via the Internet at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. Eastern Time on June 23, 2022 and ending at 11:59 p.m. Eastern Time on July 24, 2022. To access the replay of the call, telephone (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. Eastern Time today. The playback will be available until the company’s next conference call. About Rite Aid Corporation Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to Americans 365 days a year. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,300 retail pharmacy locations across 17 states. Through Elixir, we provide pharmacy benefits and services to millions of members nationwide. For more information, visit www.riteaid.com. Cautionary Statement Regarding Forward-Looking Statements Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Rite Aid's outlook and guidance for fiscal 2023; the continued impact of the global coronavirus (COVID-19) pandemic on Rite Aid’s business; Rite Aid’s store closure program; and any assumptions underlying any of the foregoing. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to: risks related to the prolonged impact of the COVID-19 global pandemic and the emerging new variants, including the government responses thereto; the impact of COVID-19 on our workforce, operations, stores, expenses, and supply chain, and the operations or behaviors of our customers, suppliers and business partners; our ability to successfully implement our store closure program and other strategies; the impact of our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms and our ability to satisfy our obligations and the other covenants contained in our debt agreements; outcome of pending or new litigation, including related to Opioids, “usual and customary” pricing or other matters; our ability to monetize the CMS receivable created in our Part D business; general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions (including changes to laws or regulations relating to labor or wages), as well as other factors that impact the markets in which we operate; the impact of private and public third-party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order; our ability to manage expenses and our investments in working capital; our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; our ability to achieve cost savings and other benefits of our restructuring efforts within our anticipated timeframe, if at all; the outcome of our continuing efforts to monitor and comply with applicable laws, regulations, policies and procedures; and our ability to partner and have relationships with health plans and health systems. These and other risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission (the “SEC”), which you are encouraged to read. To the extent that COVID-19 adversely affects our business and financial results, it may also have the effect of heightening many of such risk factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The degree to which COVID-19 may adversely affect Rite Aid’s results and operations, including its ability to achieve its outlook for fiscal 2023 guidance, will depend on numerous evolving factors and future developments, which are highly uncertain, including, but not limited to, federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 and emerging new variants and how quickly and to what extent normal economic and operating conditions can resume. As a result, the impact on Rite Aid’s financial and operating results cannot be reasonably estimated with specificity at this time, but the impact could be material. Rite Aid expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise. All references to “Company” and “Rite Aid” as used throughout this release refer to Rite Aid Corporation and its affiliates. Reconciliation of Non-GAAP Financial Measures Rite Aid separately reports financial results on the basis of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Adjusted EBITDA, Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A, which are non-GAAP financial measures. See the attached tables for a reconciliation of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Adjusted EBITDA to net income (loss), and net income (loss) per diluted share, which are the most directly comparable GAAP financial measures. Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share exclude amortization expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, gains or losses on debt modifications and retirements, LIFO adjustments, goodwill and intangible asset impairment charges, restructuring-related costs, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables. Rite Aid believes Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share serve as appropriate measures to be used in evaluating the performance of its business and help its investors better compare its operating performance over multiple periods. Adjusted EBITDA is defined as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility exit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, severance, restructuring-related costs, costs related to facility closures, gain or loss on sale of assets, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). The add back of LIFO (credit) charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share removes the entire impact of LIFO (credits) charges, and effectively reflects Rite Aid's results as if the company was on a FIFO inventory basis. Rite Aid believes Adjusted EBITDA serves as an appropriate measure in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors. Adjusted EBITDA Gross Profit includes LIFO adjustments, depreciation and amortization (COGS portion only) and other items. See the attached tables for a reconciliation of Adjusted EBITDA Gross Profit to Revenue, which is the most directly comparable GAAP financial measure. Adjusted EBITDA SG&A excludes depreciation and amortization (SG&A portion only), stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, and other items. See the attached tables for a reconciliation of Adjusted EBITDA SG&A to Revenue, which is the most directly comparable GAAP financial measure. The Company believes Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A serve as appropriate measures in evaluating the performance of its business and helps its investors better compare its operating performance with its competitors. RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Dollars in thousands) (unaudited) May 28, 2022 February 26, 2022 ASSETS Current assets: Cash and cash equivalents $ 56,060 $ 39,721 Accounts receivable, net 1,449,745 1,343,496 Inventories, net of LIFO reserve of $487,173 and $487,173 1,974,759 1,959,389 Prepaid expenses and other current assets 88,860 106,749 Total current assets 3,569,424 3,449,355 Property, plant and equipment, net 985,121 989,167 Operating lease right-of-use assets 2,723,405 2,813,535 Goodwill 879,136 879,136 Other intangibles, net 282,950 291,196 Deferred tax assets 20,071 20,071 Other assets 89,666 86,543 Total assets $ 8,549,773 $ 8,529,003 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Current maturities of long-term debt and lease financing obligations $ 5,016 $ 5,544 Accounts payable 1,461,238 1,571,261 Accrued salaries, wages and other current liabilities 787,591 780,632 Current portion of operating lease liabilities 574,392 575,651 Total current liabilities 2,828,237 2,933,088 Long-term debt, less current maturities 3,026,456 2,732,986 Long-term operating lease liabilities 2,526,607 2,597,090 Lease financing obligations, less current maturities 14,392 14,830 Other noncurrent liabilities 162,457 151,976 Total liabilities 8,558,149 8,429,970 Commitments and contingencies - - Stockholders' equity: Common stock 55,623 55,752 Additional paid-in capital 5,913,210 5,910,299 Accumulated deficit (5,961,772 ) (5,851,581 ) Accumulated other comprehensive loss (15,437 ) (15,437 ) Total stockholders' equity (8,376 ) 99,033 Total liabilities and stockholders' equity $ 8,549,773 $ 8,529,003 RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in thousands, except per share amounts) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Revenues $ 6,014,583 $ 6,160,985 Costs and expenses: Cost of revenues 4,817,854 4,876,110 Selling, general and administrative expenses 1,217,929 1,245,362 Facility exit and impairment charges 66,571 8,831 Interest expense 48,119 49,121 Loss on debt retirements, net - 396 Gain on sale of assets, net (29,196 ) (6,558 ) 6,121,277 6,173,262 Loss before income taxes (106,694 ) (12,277 ) Income tax expense 3,497 780 Net loss $ (110,191 ) $ (13,057 ) Basic and diluted loss per share: Numerator for loss per share: Net loss attributable to common stockholders - basic and diluted $ (110,191 ) $ (13,057 ) Denominator: Basic and diluted weighted average shares 54,348 53,852 Basic and diluted loss per share $ (2.03 ) $ (0.24 ) RITE AID CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 OPERATING ACTIVITIES: Net loss $ (110,191 ) $ (13,057 ) Adjustments to reconcile to net cash (used in) provided by operating activities: Depreciation and amortization 70,073 75,859 Facility exit and impairment charges 66,571 8,831 LIFO credit - (3,993 ) Change in allowances for uncollectible accounts receivable 3,763 - Gain on sale of assets, net (29,196 ) (6,558 ) Stock-based compensation expense 3,334 2,811 Loss on debt retirements, net - 396 Changes in operating assets and liabilities: Accounts receivable (104,458 ) (149,487 ) Inventories (15,827 ) 11,918 Accounts payable (137,572 ) 50,527 Operating lease right-of-use assets and operating lease liabilities (14,812 ) (5,909 ) Other assets 751 7,978 Other liabilities 15,327 34,559 Net cash (used in) provided by operating activities (252,237 ) 13,875 INVESTING ACTIVITIES: Payments for property, plant and equipment (73,176 ) (59,164 ) Intangible assets acquired (12,248 ) (5,436 ) Proceeds from dispositions of assets and investments 30,839 2,448 Proceeds from sale-leaseback transactions - 7,456 Net cash used in investing activities (54,585 ) (54,696 ) FINANCING ACTIVITIES: Net proceeds from revolver 291,000 39,000 Principal payments on long-term debt (977 ) (91,941 ) Change in zero balance cash accounts 33,691 51,957 Financing fees paid for early debt redemption - (2 ) Payments for taxes related to net share settlement of equity awards (553 ) (35 ) Deferred financing costs paid - (580 ) Net cash provided by (used in) financing activities 323,161 (1,601 ) Increase (decrease) in cash and cash equivalents 16,339 (42,422 ) Cash and cash equivalents, beginning of period 39,721 160,902 Cash and cash equivalents, end of period $ 56,060 $ 118,480 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL SEGMENT OPERATING INFORMATION (Dollars in thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Retail Pharmacy Segment Revenues (a) $ 4,345,356 $ 4,351,682 Cost of revenues (a) 3,247,999 3,181,748 Gross profit 1,097,357 1,169,934 LIFO credit - (3,993 ) FIFO gross profit 1,097,357 1,165,941 Adjusted EBITDA gross profit 1,106,652 1,168,338 Gross profit as a percentage of revenues 25.25 % 26.88 % LIFO credit as a percentage of revenues 0.00 % -0.09 % FIFO gross profit as a percentage of revenues 25.25 % 26.79 % Adjusted EBITDA gross profit as a percentage of revenues 25.47 % 26.85 % Selling, general and administrative expenses 1,117,214 1,156,039 Adjusted EBITDA selling, general and administrative expenses 1,032,970 1,073,424 Selling, general and administrative expenses as a percentage of revenues 25.71 % 26.57 % Adjusted EBITDA selling, general and administrative expenses as a percentage of revenues 23.77 % 24.67 % Cash interest expense 45,244 46,024 Non-cash interest expense 2,875 3,097 Total interest expense 48,119 49,121 Adjusted EBITDA 73,682 94,914 Adjusted EBITDA as a percentage of revenues 1.70 % 2.18 % Pharmacy Services Segment Revenues (a) $ 1,725,857 $ 1,872,282 Cost of revenues (a) 1,626,485 1,757,341 Gross profit 99,372 114,941 Gross profit as a percentage of revenues 5.76 % 6.14 % Adjusted EBITDA 26,448 43,963 Adjusted EBITDA as a percentage of revenues 1.53 % 2.35 % (a) - Revenues and cost of revenues include $56,630 and $62,979 of inter-segment activity for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively, that is eliminated in consolidation. RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (In thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Reconciliation of net loss to adjusted EBITDA: Net loss $ (110,191 ) $ (13,057 ) Adjustments: Interest expense 48,119 49,121 Income tax expense 3,497 780 Depreciation and amortization 70,073 75,859 LIFO credit - (3,993 ) Facility exit and impairment charges 66,571 8,831 Loss on debt retirements, net - 396 Merger and Acquisition-related costs - 3,886 Stock-based compensation expense 3,334 2,811 Restructuring-related costs 22,646 5,932 Inventory write-downs related to store closings 7,955 472 Litigation and other contractual settlements 18,271 14,000 Gain on sale of assets, net (29,196 ) (6,558 ) Other (949 ) 397 Adjusted EBITDA $ 100,130 $ 138,877 Percent of revenues 1.66 % 2.25 % RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION ADJUSTED NET (LOSS) INCOME (Dollars in thousands, except per share amounts) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Net loss $ (110,191 ) $ (13,057 ) Add back - Income tax expense 3,497 780 Loss before income taxes (106,694 ) (12,277 ) Adjustments: Amortization expense 20,626 20,460 LIFO credit - (3,993 ) Loss on debt retirements, net - 396 Merger and Acquisition-related costs - 3,886 Restructuring-related costs 22,646 5,932 Litigation and other contractual settlements 18,271 14,000 Adjusted (loss) income before income taxes (45,151 ) 28,404 Adjusted income tax (benefit) expense (a) (12,322 ) 7,470 Adjusted net (loss) income $ (32,829 ) $ 20,934 Adjusted net (loss) income per diluted share: Numerator for adjusted net (loss) income per diluted share: Adjusted net (loss) income $ (32,829 ) $ 20,934 Denominator: Basic weighted average shares 54,348 53,852 Outstanding options and restricted shares, net - 971 Diluted weighted average shares 54,348 54,823 Net loss per diluted share $ (2.03 ) $ (0.24 ) Adjusted net (loss) income per diluted share $ (0.60 ) $ 0.38 (a) The fiscal year 2023 and 2022 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL's, state credits and valuation allowance, was used for the thirteen weeks ended May 28, 2022 and May 29, 2021, respectively. RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT AND RECONCILIATION OF ADJUSTED EBITDA SELLING, GENERAL AND ADMINISTRATIVE EXPENSES- RETAIL PHARMACY SEGMENT (In thousands) (unaudited) Thirteen weeks endedMay 28, 2022 Thirteen weeks endedMay 29, 2021 Reconciliation of adjusted EBITDA gross profit: Revenues $ 4,345,356 $ 4,351,682 Gross Profit 1,097,357 1,169,934 Addback: LIFO credit - (3,993 ) Depreciation and amortization (cost of goods sold portion only) 2,893 2,097 Other 6,402 300 Adjusted EBITDA gross profit $ 1,106,652 $ 1,168,338 Percent of revenues 25.47 % 26.85 % Reconciliation of adjusted EBITDA selling, general and administrative expenses: Revenues $ 4,345,356 $ 4,351,682 Selling, general and administrative expenses 1,117,214 1,156,039 Less: Depreciation and amortization (SG&A portion only) 53,215 59,768 Stock-based compensation expense 3,102 2,771 Merger and Acquisition-related costs - 3,886 Restructuring-related costs 17,371 1,621 Litigation and other contractual settlements 9,952 14,000 Other 604 569 Adjusted EBITDA selling, general and administrative expenses $ 1,032,970 $ 1,073,424 Percent of revenues 23.77 % 24.67 % Adjusted EBITDA $ 73,682 $ 94,914 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited) Guidance Range Low High Total Revenues $ 23,600,000 $ 24,000,000 Pharmacy Services Segment Revenues $ 6,250,000 $ 6,350,000 Gross Capital Expenditures $ 250,000 $ 250,000 Reconciliation of net loss to adjusted EBITDA: Net loss $ (246,300 ) $ (203,300 ) Adjustments: Interest expense 210,000 210,000 Income tax benefit (15,000 ) (18,000 ) Depreciation and amortization 290,000 290,000 LIFO charge 15,000 15,000 Facility exit and impairment charges 130,000 130,000 Restructuring-related costs 60,000 60,000 Litigation and other contractual settlements 18,300 18,300 Gain on sale of assets, net (35,000 ) (35,000 ) Other 33,000 33,000 Adjusted EBITDA $ 460,000 $ 500,000 RITE AID CORPORATION AND SUBSIDIARIES SUPPLEMENTAL INFORMATION RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET LOSS GUIDANCE YEAR ENDING MARCH 4, 2023 (In thousands) (unaudited) Guidance Range Low High Net loss $ (246,300 ) $ (203,300 ) Add back - income tax benefit (15,000 ) (18,000 ) Loss before income taxes (261,300 ) (221,300 ) Adjustments: Amortization expense 79,000 79,000 LIFO charge 15,000 15,000 Restructuring-related costs 60,000 60,000 Litigation and other contractual settlements 18,300 18,300 Adjusted loss before adjusted income taxes (89,000 ) (49,000 ) Adjusted income tax benefit (24,000 ) (13,000 ) Adjusted net loss $ (65,000 ) $ (36,000 ) Diluted adjusted net loss per share $ (1.19 ) $ (0.66 ) View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005204/en/
INVESTORS: Byron Purcell (717) 975-3710 investor@riteaid.com MEDIA: Joy Errico Seusing (203) 970-5559 press@riteaid.com